Atrial Fibrillation News and Research

RSS
Atrial fibrillation (AF) is the most common arrhythmia. An arrhythmia is a problem with the speed or rhythm of the heartbeat. A disorder in the heart’s electrical system causes AF and other types of arrhythmia. AF occurs when rapid, disorganized electrical signals in the heart’s two upper chambers, called the atria, cause them to contract very fast and irregularly (this is called fibrillation). As a result, blood pools in the atria and isn’t pumped completely into the heart’s two lower chambers, called the ventricles. When this happens, the heart’s upper and lower chambers don’t work together as they should. Often, people who have AF may not even feel symptoms. However, even when not noticed, AF can lead to an increased risk of stroke. In many patients, particularly when the rhythm is extremely rapid, AF can cause chest pain, heart attack, or heart failure. AF may occur rarely or every now and then, or it may become a persistent or permanent heart rhythm lasting for years.
Catheter ablation treatment reduces risks associated with atrial fibrillation

Catheter ablation treatment reduces risks associated with atrial fibrillation

St. Jude Medical announces FDA clearance and CE Mark approval for EnSite Derexi module

St. Jude Medical announces FDA clearance and CE Mark approval for EnSite Derexi module

ARYx Therapeutics decreases first-quarter net loss to $6.4 million

ARYx Therapeutics decreases first-quarter net loss to $6.4 million

Stereotaxis to be featured prominently in 31st HRS

Stereotaxis to be featured prominently in 31st HRS

Children and young adults account for as many as 10% of all stroke cases

Children and young adults account for as many as 10% of all stroke cases

St. Jude Medical to display new products, clinical solutions at Heart Rhythm 2010

St. Jude Medical to display new products, clinical solutions at Heart Rhythm 2010

Merck hosts R&D and Business Briefing

Merck hosts R&D and Business Briefing

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

Cardiome Pharma records $15.5M net income for first-quarter 2010

Cardiome Pharma records $15.5M net income for first-quarter 2010

FDA approves software upgrade to Boston Scientific's LATITUDE Patient Management system

FDA approves software upgrade to Boston Scientific's LATITUDE Patient Management system

Cardima implements reverse stock split

Cardima implements reverse stock split

LifeWatch Services to launch remote iPad ECG report TeleViewer application

LifeWatch Services to launch remote iPad ECG report TeleViewer application

LifeWatch Services to unveil advanced AF TeleClinic service at HRS Annual Meeting

LifeWatch Services to unveil advanced AF TeleClinic service at HRS Annual Meeting

BIOTRONIK launches TactiCath irrigated RF contact force ablation catheter for treating AF

BIOTRONIK launches TactiCath irrigated RF contact force ablation catheter for treating AF

Endosense commences enrollment in EFFICAS I study with TactiCath force-sensing catheter

Endosense commences enrollment in EFFICAS I study with TactiCath force-sensing catheter

NewCardio to unveil patented CardioBip technology at HRS Annual Scientific Sessions

NewCardio to unveil patented CardioBip technology at HRS Annual Scientific Sessions

AGA Medical first-quarter net sales increase 15.4% to $51.3 million

AGA Medical first-quarter net sales increase 15.4% to $51.3 million

MicroStockProfit.com releases Hansen Medical investment report

MicroStockProfit.com releases Hansen Medical investment report

Medtronic completes enrollment in first of two CURE-AF clinical trials

Medtronic completes enrollment in first of two CURE-AF clinical trials

DeCODE scientists discover common SNPs that increase number of CPD and risk of lung cancer

DeCODE scientists discover common SNPs that increase number of CPD and risk of lung cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.